Latest - Page 2 of 4 - Rivervest - News & Press / Case Studies / Articles

News & Press

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

News & Press

RiverVest Venture Partners Expands Scientific Advisory Board

News & Press

St. Louis Venture Fund Makes $15 Million Bet on its Hometown

News & Press

RiverVest Venture Partners Closes on $15 Million Biopharma Pre-Seed Fund

News & Press

RiverVest Venture Partners co-leads $86 million Series A financing for St. Louis-founded startup Tioma

News & Press

Nancy A. Hong Joins RiverVest Venture Partners as Life Sciences VC Opens Office in San Diego

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio – 4/27/2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors. – 4/21/2020
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline – 4/2/2020
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update – 3/12/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing – 3/2/2020
Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth – 2/19/2020
InterVene, Inc. Wins TCT 2019 Shark Tank Innovation Competition – 9/29/2019
Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease – 2/18/2020
Mirum Pharmaceuticals Announces Pricing of Public Offering – 1/8/2020
Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat – 12/16/2019
Allakos Reports Third Quarter 2019 Financial Results – 11/12/2019
Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome – 10/28/2019
Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia – 09/19/2019
Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients – 9/16/2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia – 9/16/2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications – 9/9/2019
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE) – 8/5/2019
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock – 8/9/2019
Allakos Reports Second Quarter 2019 Financial Results – 8/5/2019
Allakos Announces Proposed Public Offering of Common Stock
Mirum Pharmaceuticals Announces Pricing of Initial Public Offering
InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure
Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases – 5/20/2019

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Learn More

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

RiverVest Venture Partners Expands Scientific Advisory Board

St. Louis Venture Fund Makes $15 Million Bet on its Hometown

RiverVest Venture Partners Closes on $15 Million Biopharma Pre-Seed Fund

RiverVest Venture Partners co-leads $86 million Series A financing for St. Louis-founded startup Tioma

Nancy A. Hong Joins RiverVest Venture Partners as Life Sciences VC Opens Office in San Diego

Get Directions

Get Directions

Get Directions